|ASMB -- USA Stock|| |
USD 46.17 1.87 3.89%
Mr. David J. Barrett CPA, is Chief Financial Officer, Chief Operating Officer of Company. From April 2006 to September 2009, Mr. Barrett served as Chief Financial Officer of NeuroHitech, Inc., a public company focused on developing, marketing and distributing branded and generic pharmaceutical products. From September 2003 to April 2006, Mr. Barrett was the Chief Financial OfficerVice President of Finance of Overture Asset Managers and Overture Financial Services, which, at the time, was a startup asset management firm that assembled investment products and platforms to distribute turnkey and unbundled investment solutions to financial intermediaries and institutional investors. From July 1999 to September 2003, Mr. Barrett was employed as a Manager at Deloitte Touche, LLP. Mr. Barrett also is a director of Coronado Biosciences, Inc., a biopharmaceutical Company
Age: 38 COO Since 2015
Barrett received his B.S. in Accounting and Economics and his M.S. in Accounting from the University of Florida. He is a certified public accountant.
David Barrett Latest Insider Activity
The company has return on total asset (ROA)
of (23.67) %
which means that it has lost $23.67 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (53.01) %
meaning that it created substantial loss on money invested by shareholders.
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. Assembly Biosciences operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 85 people.Assembly Biosciences (ASMB) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 85 people. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.
Assembly Biosciences Leadership Team
|Uri Lopatin, President, Ph.D|
|Helen Kim, Director, MBA|
|Myron Holubiak, Director|
|Lee Arnold, Executive, Ph.D|
|Anthony Altig, Director|
|Richard Colonno, Executive|
|Graham Cooper, COO, MBA|
|William Ringo, Chairman, MBA|
|Susan Mahony, Director|
|Richard DiMarchi, Director, Ph.D|
|Miguel Barbosa, Executive, Ph.D|
|Thomas Rollins, Executive|
|Mark Auerbach, Director|
|Derek Small, CEO|
|Alan Lewis, Director, Ph.D|
|David Barrett, COO|
Stock Performance Indicators
Most of Macroaxis users are presently bullish on Assembly Biosciences. What is your sentiment towards investing in Assembly Biosciences? Are you bullish or bearish?
and pair trading evaluation for Assembly Biosciences and NantKwest
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return